Emmaus Life Sciences Inc (EMMA)
0.013
0.00 (0.00%)
USD |
OTCM |
May 23, 16:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.8303M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -86.47% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.0695 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.5078 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
Edit
| Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering. |
| URL | https://www.emmausmedical.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jul. 03, 2025 (est.) |
| Last Earnings Release | May. 15, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering. |
| URL | https://www.emmausmedical.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jul. 03, 2025 (est.) |
| Last Earnings Release | May. 15, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |